Compared side by side
Tirzepatide vs cagrilintide: how they differ
The short answer
Both are weekly shots, on different hormones: tirzepatide activates the GLP-1 and GIP receptors, and cagrilintide is a long-acting analogue of amylin, the fullness hormone the pancreas releases with insulin, which promotes fullness and slows stomach emptying. Tirzepatide is FDA-approved, as Mounjaro and Zepbound; cagrilintide isn’t approved on its own, and the crowd mostly runs it beside a GLP-1 drug. In trials on its own, cagrilintide’s higher doses led to about 10–12% weight loss, and tirzepatide’s 15 mg up to 22.5% at 72 weeks (SURMOUNT-1).
Side by side
| Compared | Tirzepatide | Cagrilintide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Mounjaro, Zepbound, LY3298176 | Cagri, AM833, NNC0174-0833 |
| What it is | The first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks). | A long-acting version of amylin, the fullness hormone the pancreas releases alongside insulin, given as a weekly shot. |
| How it works | Dual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management. | Long-acting, lipidated analogue of amylin, the satiety hormone the pancreas releases with insulin. It activates amylin receptors and the calcitonin receptor (a non-selective amylin agonist); amylin promotes fullness, slows stomach emptying and holds back glucagon after meals. A fatty-acid chain stretches its half-life to about a week, so it is a weekly shot, usually run beside a GLP-1. Not approved on its own: it is the amylin half of Novo Nordisk's CagriSema. |
| Commonly reported | Very strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound). | Feeling full sooner and portions shrinking, with nausea or constipation after step-ups and some injection-site reactions. It is not approved on its own. |
| Studied range | FDA label: 2.5–15 mg, starting dose 2.5 mg. | Research range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation. |
| How often | Weekly | Weekly |
| Half-life | ~5 days (FDA label) | ~1 week (measured in people: 159–195 hours in a phase 1b trial) |
| Route | SubQ injection | SubQ injection |
| Typical run | FDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose. | Trials run it continuously: 26 weeks in phase 2, 68 weeks in phase 3. Community use is mostly as a weekly add-on to a GLP-1. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue | Nausea, constipation, diarrhea, injection-site reactions |
- Category
- TirzepatideMetabolic & GLP-1
- CagrilintideMetabolic & GLP-1
- Also known as
- TirzepatideMounjaro, Zepbound, LY3298176
- CagrilintideCagri, AM833, NNC0174-0833
- What it is
- TirzepatideThe first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks).
- CagrilintideA long-acting version of amylin, the fullness hormone the pancreas releases alongside insulin, given as a weekly shot.
- How it works
- TirzepatideDual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management.
- CagrilintideLong-acting, lipidated analogue of amylin, the satiety hormone the pancreas releases with insulin. It activates amylin receptors and the calcitonin receptor (a non-selective amylin agonist); amylin promotes fullness, slows stomach emptying and holds back glucagon after meals. A fatty-acid chain stretches its half-life to about a week, so it is a weekly shot, usually run beside a GLP-1. Not approved on its own: it is the amylin half of Novo Nordisk's CagriSema.
- Commonly reported
- TirzepatideVery strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound).
- CagrilintideFeeling full sooner and portions shrinking, with nausea or constipation after step-ups and some injection-site reactions. It is not approved on its own.
- Studied range
- TirzepatideFDA label: 2.5–15 mg, starting dose 2.5 mg.
- CagrilintideResearch range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation.
- How often
- TirzepatideWeekly
- CagrilintideWeekly
- Half-life
- Tirzepatide~5 days (FDA label)
- Cagrilintide~1 week (measured in people: 159–195 hours in a phase 1b trial)
- Route
- TirzepatideSubQ injection
- CagrilintideSubQ injection
- Typical run
- TirzepatideFDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose.
- CagrilintideTrials run it continuously: 26 weeks in phase 2, 68 weeks in phase 3. Community use is mostly as a weekly add-on to a GLP-1.
- Evidence
- TirzepatideEstablished: clinical trials or FDA-approved use exists
- CagrilintideEstablished: clinical trials or FDA-approved use exists
- Common side effects
- TirzepatideNausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue
- CagrilintideNausea, constipation, diarrhea, injection-site reactions
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Tirzepatide
- Day 1–28 · 2.5 mg Getting your gut acclimated
- Day 29–56 · 5 mg First therapeutic dose — weight drops
- Day 57–112 · 7.5 mg Dual agonism in full effect
- Day 113–168 · 12.5 mg Max titration reached
- Day 169–504 Weeks 24 to 72: where most people plateau
- Day 365+ A maintenance medication, not a course
Cagrilintide
- Day 1–28 · 0.25 mg The 0.25 mg start
- Day 29–364 · 0.5 mg 0.5 mg, the second step
- Day 57–364 · 1 mg 1 mg, the middle step
- Day 85–364 · 1.7 mg 1.7 mg, the step before 2.4 mg
- Day 113+ · 2.4 mg 2.4 mg, the phase 3 dose
Together or one or the other
Tirzepatide and cagrilintide are a common stack: cagrilintide lists tirzepatide among its common stacks.
Animal · Cagrilintide
With retatrutide or tirzepatide: the crowd's stacks
Cagrilintide beside retatrutide or tirzepatide is a common crowd stack, on the same logic as CagriSema. No trial in people has tested these pairs; in obese rats, cagrilintide plus retatrutide lost more weight than either alone.
Questions people ask
How long do tirzepatide and cagrilintide last?
The half-life of tirzepatide is ~5 days (FDA label). The half-life of cagrilintide is ~1 week (measured in people: 159–195 hours in a phase 1b trial).
How often are tirzepatide and cagrilintide taken?
Tirzepatide: weekly. Route: SubQ injection. Cagrilintide: weekly. Route: SubQ injection.
How are tirzepatide and cagrilintide dosed in research?
The FDA label range for tirzepatide is 2.5–15 mg, with a 2.5 mg starting dose. The research range for cagrilintide is 0.25–2.4 mg, with a 0.25 mg starting dose. Studied in research — not a recommendation.
What are the common side effects of tirzepatide and cagrilintide?
For tirzepatide, the library lists: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue. For cagrilintide: nausea, constipation, diarrhea, injection-site reactions.
Are tirzepatide and cagrilintide taken together?
Tirzepatide and cagrilintide are a common stack: cagrilintide lists tirzepatide among its common stacks. Cagrilintide beside retatrutide or tirzepatide is a common crowd stack, on the same logic as CagriSema. No trial in people has tested these pairs; in obese rats, cagrilintide plus retatrutide lost more weight than either alone.